Circulating insulin-like growth factor-binding protein 3 as prognostic biomarker in liver cirrhosis

Table 1 Demographic, clinical and biochemical features of included patients n (%)

	Stable cirrhosis (n = 138)	Acute decompensation (n = 189)
Age; yr, mean ± SD	53.62 ± 12.52	53.58 ± 11.56
Caucasians	128 (92.8)	129 (68.6)
Male gender	97 (70.3)	138 (73.0)
Etiology of cirrhosis
Alcohol	42 (30.4)	68 (36.0)
Hepatitis C	50 (36.2)	78 (41.3)
Hepatitis B	6 (4.3)	8 (4.2)
Cryptogenic	14 (10.1)	15 (7.9)
Other	26 (18.8)	20 (10.6)
Previous decompensation	104 (75.4)	120 (63.5)
Active alcoholism	5 (3.6)	68 (36.0)
Propranolol	87(63.0)	74 (40.2)
PPI	69 (50.0)	43 (23.4)
Complication at evaluation
Ascites	28 (20.3)	92 (48.7)
Hepatic encephalopathy	14 (10.1)	112 (59.3)
Gastrointestinal bleeding	0	99 (52.4)
Bacterial infection	0	50 (26.6)
ACLF	0	45 (23.8)
Laboratory data
Leucocyte count (× 109), median	4.90	7.20
Sodium (meq/L), median	138	135
Creatinine (mg/dL), median	0.90	1.1
INR, median	1.20	1.41
Albumin (g/dL), mean ± SD	3.44 ± 0.46	2.35 ± 0.69
CRP (mg/L), median	3.5	10.05
Total bilirubin (mg/dL), median	1.00	2.10
IGFBP-3 (mcg/mL), median	1.69	0.94
Child-Pugh classification
A	92 (66.7)	23 (12.2)
B	43 (31.2)	91 (48.1)
C	3 (2.2)	75 (39.7)
MELD score, mean ± SD	9.84 ± 2.28	16.32 ± 6.53

PPI: Proton-pump inhibitors; ACFL: Acute-on-chronic liver failure; INR: International normalized ratio; CRP: C-reactive protein; IGFBP-3: Insulin-like growth factor-binding protein 3; MELD: Model for end-stage liver disease.